Asclepius (Suzhou) Technology Company Group Co.; Ltd.
发明人:
Huashun Li,Baoyong Ren,Peng Liu
申请号：
US16430984
公开号：
US20190309050A1
申请日:
2019.06.04
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present invention relates to the field of biomedical technology, in particular to a fusion protein Slit2D2(C386S)-HSA and use thereof in the treatment and/or prevention of fibrotic diseases. In the fusion protein, the amino acid residue is mutated on the basis of the Slit2D2 domain, which improves the stability of the fusion protein compared with the native protein. The above fusion protein is obtained by fusing Slit2D2(C386S) with HSA protein, which prolongs the metabolism time of the drug while improving the stability of the drug. The fusion protein provided by the present invention is more effective than the positive control drug in the prevention and treatment of fibrotic diseases, particularly pulmonary fibrosis, and shows good drug-forming properties.
